Ensysce Biosciences (ENSC) 10-Q 15 May 23 2023 Q1 Quarterly report Financial data

Cover

Cover - shares	3 Months Ended
	Mar. 31, 2023	May 10, 2023
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2023
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31
Entity File Number	001-38306
Entity Registrant Name	Ensysce Biosciences, Inc.
Entity Central Index Key	0001716947
Entity Tax Identification Number	82-2755287
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	7946 Ivanhoe Avenue
Entity Address, Address Line Two	Suite 201
Entity Address, City or Town	La Jolla
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92037
City Area Code	(858)
Local Phone Number	263-4196
Title of 12(b) Security	Common Stock, $0.0001 par value per share
Trading Symbol	ENSC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Elected Not To Use the Extended Transition Period	false
Entity Shell Company	false
Entity Bankruptcy Proceedings, Reporting Current	true
Entity Common Stock, Shares Outstanding		1,284,583

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 1,415,765	$ 3,147,702
Unbilled receivable	289,312	276,821
Right-of-use asset	19,015	27,165
Prepaid expenses and other current assets	1,646,553	1,847,481
Total current assets	3,370,645	5,299,169
Other assets	544,217	585,883
Total assets	3,914,862	5,885,052
Current liabilities:
Accounts payable	1,598,166	2,943,791
Accrued expenses and other liabilities	2,358,682	2,226,494
Lease liability	19,120	27,315
Notes payable and accrued interest ($0 and $4,063,431 at fair value at March 31, 2023 and December 31, 2022, respectively)		4,266,610
Total current liabilities	3,975,968	9,464,210
Long-term liabilities:
Notes payable, net of current portion (at fair value)		140,148
Liability classified warrants	91,318	310,346
Total long-term liabilities	91,318	450,494
Total liabilities	4,067,286	9,914,704
Stockholders’ deficit
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at March 31, 2023 (unaudited) and December 31, 2022
Common stock, $0.0001 par value, 250,000,000 shares authorized at March 31, 2023 (unaudited) and December 31, 2022; 1,284,664 and 534,571 shares issued at March 31, 2023 (unaudited) and December 31, 2022, respectively; 1,284,583 and 534,490 shares outstanding at March 31, 2023 (unaudited) and December 31, 2022, respectively	128	53
Additional paid-in capital	113,293,834	107,216,566
Accumulated deficit	(113,127,237)	(110,931,063)
Total Ensysce Biosciences, Inc. stockholders’ equity (deficit)	166,725	(3,714,444)
Noncontrolling interests in stockholders’ deficit	(319,149)	(315,208)
Total stockholders’ deficit	(152,424)	(4,029,652)
Total liabilities and stockholders’ deficit	$ 3,914,862	$ 5,885,052

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Notes payable and accrued interest	$ 0	$ 4,063,431
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	1,284,664	534,571
Common stock, shares outstanding	1,284,583	534,490

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Federal grants	$ 789,635	$ 603,098
Operating expenses:
Research and development	1,796,015	3,140,096
General and administrative	1,554,855	2,265,806
Total operating expenses	3,350,870	5,405,902
Loss from operations	(2,561,235)	(4,802,804)
Other income (expense):
Change in fair value of convertible notes	146,479	2,767,178
Change in fair value of liability classified warrants	219,028	2,794,398
Loss on debt conversions		(1,702,642)
Interest expense, net	(1,497)	(15,021)
Other income and expense, net	5,419	7,966
Total other income, net	369,429	3,851,879
Net loss	(2,191,806)	(950,925)
Net loss attributable to noncontrolling interests	(3,941)	182
Deemed dividend related to warrants down round provision	8,309	715,579
Net loss attributable to common stockholders	$ (2,196,174)	$ (1,666,686)
Net loss per basic and diluted share:
Net loss per share attributable to common stockholders, basic and diluted	$ (2.08)	$ (14.66)
Weighted average common shares outstanding, basic and diluted	1,054,202	113,696

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2021	$ 10	$ 77,967,314	$ (85,845,567)	$ (279,815)	$ (8,158,058)
Balance, shares at Dec. 31, 2021	102,678
Consultant compensation	$ 0	54,250			54,250
Consultant compensation, shares	208
Conversion of convertible notes	$ 2	8,075,341			8,075,343
Conversions of convertible notes, shares	19,618
Public offering, net	$ 0	0
Public offering, net, shares	2,280
Stock-based compensation		2,090,663			2,090,663
Deemed dividend related to warrants down round provision		715,579	(715,579)
Net loss			(951,107)	182	(950,925)
Balance at Mar. 31, 2022	$ 12	88,903,147	(87,512,253)	(279,633)	1,111,273
Balance, shares at Mar. 31, 2022	124,784
Balance at Dec. 31, 2022	$ 53	107,216,566	(110,931,063)	(315,208)	(4,029,652)
Balance, shares at Dec. 31, 2022	534,490
Conversion of convertible notes	$ 41	3,056,851			3,056,892
Conversions of convertible notes, shares	408,582
Public offering, net	$ 30	2,689,022			2,689,052
Public offering, net, shares	297,619
Stock-based compensation		117,133			117,133
Deemed dividend related to warrants down round provision		8,309	(8,309)
Net loss			(2,187,865)	(3,941)	(2,191,806)
Settlement of restricted stock units
Settlement of restricted stock units, shares	312
Settlement of commitment fee	$ 4	399,996			400,000
Settlement of commitment fee, shares	44,444
Transaction costs associated with public offering		(194,043)			(194,043)
Reverse split fractional shares
Reverse split fractional shares, shares	(864)
Balance at Mar. 31, 2023	$ 128	$ 113,293,834	$ (113,127,237)	$ (319,149)	$ (152,424)
Balance, shares at Mar. 31, 2023	1,284,583

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (2,191,806)	$ (950,925)
Adjustments to reconcile net loss to net cash used in operating activities:
Gain on sale of asset		(4,500)
Accrued interest	1,497	15,021
Change in fair value of convertible notes	(146,479)	(2,767,178)
Change in fair value of liability classified warrants	(219,028)	(2,794,398)
Loss on debt conversions		1,702,642
Stock-based compensation	117,133	402,434
Lease cost	(46)	(46)
Changes in operating assets and liabilities:
Unbilled receivable	(12,491)	(366,880)
Prepaid expenses and other assets	242,594	581,840
Accounts payable	(1,345,624)	658,526
Accrued expenses and other liabilities	(52,669)	86,450
Net cash used in operating activities	(3,606,919)	(3,437,014)
Cash flows from investing activities:
Proceeds from sale of assets		4,500
Net cash provided by investing activities		4,500
Cash flows from financing activities:
Proceeds public offering, net	2,689,052
Transaction costs associated with public offering	(194,043)
Repayment of convertible notes	(415,351)
Repayment of financed insurance premiums	(204,676)	(391,270)
Net cash provided by (used in) financing activities	1,874,982	(391,270)
Decrease in cash and cash equivalents	(1,731,937)	(3,823,784)
Cash and cash equivalents beginning of period	3,147,702	12,264,736
Cash and cash equivalents end of period	1,415,765	8,440,952
Supplemental cash flow information:
Income tax payments
Supplemental disclosure of non-cash investing and financing activities:
Stock-based compensation		1,742,479
Conversions of convertible notes into common stock	3,056,892	6,372,701
Cash true-up liability	584,857
Settlement of commitment fee in shares	400,000
Deemed dividend related to warrants down round provision	$ 8,309	$ 715,579

ORGANIZATION AND PRINCIPAL ACTI

ORGANIZATION AND PRINCIPAL ACTIVITIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
ORGANIZATION AND PRINCIPAL ACTIVITIES	NOTE 1 – ORGANIZATION AND PRINCIPAL ACTIVITIES Ensysce Biosciences, Inc. (“Ensysce”), along with its 79.2 TM TM In 2020, the Company commenced an initiative to develop a therapeutic for the treatment of certain coronavirus infections through the formation of a separate entity, EBIR, a Delaware corporation. Pursuant to the certificate of incorporation, EBIR was authorized to issue 1,000,000 0.001 100,000 0.001 79.2 19.8 1.0 The Company currently operates in one business segment, which is pharmaceuticals. The Company is not organized by market and is managed and operated as one business. A single management team reports to the chief operating decision maker, the Chief Executive Officer.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	NOTE 2 - BASIS OF PRESENTATION The consolidated financial statements have been prepared in accordance with GAAP and pursuant to the rules and regulations of the SEC. The consolidated financial statements include the accounts of Ensysce Biosciences, Inc. and its subsidiaries. All intercompany balances and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments considered necessary for a fair presentation have been included in the consolidated financial statements. Operating results for the three months ended March 31, 2023, are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim unaudited consolidated financial statements have been prepared under the presumption that users of the interim financial information have either read or have access to the audited consolidated financial statements for the fiscal year ended December 31, 2022, which may be found in the Company’s Form 10-K filed with the SEC on March 30, 2023. Reverse stock split In March 2023, the Company completed a 1-for-12 reverse split Going concern The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has not generated any product revenue and had an accumulated deficit of $ 113.1 In December 2020, the Company executed the GEM Agreement. Under the agreement, the investor agreed to provide the Company with a share subscription facility of up to $ 60.0 4,608 2,402.40 1.2 0.8 0.4 0.8 0.4 While the Company believes in the viability of its strategy to ultimately realize revenues and in its ability to raise additional funds, management cannot be certain that additional funding will be available on acceptable terms, or at all. The Company’s ability to continue as a going concern is dependent upon its ability to obtain adequate financing and achieve profitable operations. As a result, these plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months following the date these consolidated financial statements were issued. The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of estimates and assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable. Cash and cash equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents. Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss. Property and equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five six years Derivative financial instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet. Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of March 31, 2023 and December 31, 2022, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes and elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo simulation, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo simulation. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes. 2022 Notes In July 2022 the Company issued convertible notes and the 2022 Notes are accounted for under ASC 480 – Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of March 31, 2023 and December 31, 2022. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 March 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants $ 91,318 $ - $ - $ 91,318 Total $ 91,318 $ - $ - $ 91,318 Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 - - 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the quarter ended March 31, 2023: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible note Liability classified warrants Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346 Conversions (3,056,892 ) (3,056,892 ) - Cash payments (415,351 ) (415,351 ) - Cash true-up liability (584,857 ) (584,857 ) - Change in fair value (365,507 ) (146,479 ) (219,028 ) Fair value, March 31, 2023 $ 91,318 $ - $ 91,318 Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.7 In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2023 2022 Three Months Ended March 31, 2023 2022 MPAR $ 481,279 $ 504,470 TAAP/OUD 308,356 98,628 Total $ 789,635 $ 603,098 Revenue $ 789,635 $ 603,098 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded. Research and development costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. General and administrative expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees. Stock-based compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2023, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards. Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense. Earnings per share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2023 2022 Three Months Ended March 31, 2023 2022 Stock options 26,354 24,111 RSUs 691 1,788 Warrants 858,609 87,878 Convertible notes - 5,437 Total 885,654 119,214 Anti-dilutive weighted average shares 885,654 119,214 Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company adopted the standard with an effective date of January 1, 2023 and the adoption did not have a significant impact on the consolidated financial statements.

PREPAID EXPENSES AND OTHER CURR

PREPAID EXPENSES AND OTHER CURRENT ASSETS	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
PREPAID EXPENSES AND OTHER CURRENT ASSETS	NOTE 4 – PREPAID EXPENSES AND OTHER CURRENT ASSETS SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid research and development $ 1,180,547 $ 1,300,473 Prepaid insurance 314,990 445,583 Other prepaid expenses 151,016 101,425 Total prepaid expenses and other current assets $ 1,646,553 $ 1,847,481

ACCRUED EXPENSES AND OTHER LIAB

ACCRUED EXPENSES AND OTHER LIABILITIES	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER LIABILITIES	NOTE 5 – ACCRUED EXPENSES AND OTHER LIABILITIES SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES March 31, 2023 December 31, 2022 Accrued research and development $ 1,293,348 $ 1,332,713 Share subscription facility commitment fees - 400,000 Professional fees 393,077 421,530 Other accrued liabilities 672,257 72,251 Total accrued expenses and other liabilities $ 2,358,682 $ 2,226,494

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 6 – COMMITMENTS AND CONTINGENCIES Purchase Commitments As of March 31, 2023, the Company’s commitments included an estimated $ 20.4 Litigation As of March 31, 2023 and December 31, 2022, there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Lease The Company’s current lease agreement (as amended) has a term that extends through October 31, 2023 with no option to renew. As of March 31, 2023, the future lease payments totaled $ 19,120 8,375 7,834

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended
	Mar. 31, 2023
Debt Disclosure [Abstract]
NOTES PAYABLE	NOTE 7 – NOTES PAYABLE The Company’s outstanding debt balance was zero The following table provides a summary of the Company’s outstanding debt as of December 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2022 Notes $ 3,905,264 $ 10,544 $ 287,771 $ 4,203,579 Financed insurance 195,273 7,906 - 203,179 Total $ 4,100,537 $ 18,450 $ 287,771 $ 4,406,758 The interest expense recognized for financed insurance was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2023 2022 Three months ended March 31, 2023 2022 Stated interest accrual $ 1,497 $ 2,004 Total $ 1,497 $ 2,004 2021 Notes On September 24, 2021, the Company entered into an agreement with institutional investors to issue the 2021 Notes. The agreement provides for two closings: the first closing for $ 5.3 4.6 10.6 9.4 The notes included interest at a rate of 5% 6% The Company elected to apply the fair value option to the measurement of the 2021 Notes. The total initial fair value of the debt at issuance was $ 15.9 1.9 1.0 0.9 8% The 2021 Notes were settled on October 11, 2022 and were not outstanding during the quarter ending March 31, 2023. 2022 Notes On June 30, 2022, the Company entered into an $ 8.0 4.24 4.0 On the issuance date, the Company assessed the probability of the potential settlement scenarios under the terms of the 2022 Notes and determined that the predominant settlement feature of the 2022 Notes was the redemption feature into shares of the Company’s common stock issuable at the lower of the conversion price or 92% The Company recorded the 2022 Notes at an initial fair value of $ 12.09 3.6 1.1 6% 0.5 0.6 In connection with each of the first and second closings of the 2022 Notes the Company also issued warrants to purchase 38,894 170.04 five years 187.20 The proceeds of the 2022 Notes were used for working capital purposes subject to certain customary restrictions are secured by the Company’s rights to its patents and licenses. The Company is restricted from issuing certain additional debt or equity without the prior written consent of the holders for certain specified periods set forth in the 2022 Notes. If, at any time while the 2022 Notes are outstanding, the Company carries out one or more capital raises in excess of $ 5.0 20% 8% The 2022 Notes were scheduled to mature on December 29, 2023 February 7, 2024 6% 6% The following table provides a summary of the Company’s 2022 Notes conversions during the quarter ended March 31, 2023: SCHEDULE OF CONVERSION DEBT Shares Weighted Average Conversion Price Conversion Value During the quarter ended March 31, 2023 408,582 $ 7.48 $ 3,056,892 In January 2023, the Company entered into a letter agreement to reduce the conversion price for the remaining balance of the Company’s outstanding 2022 Notes from $ 24.07 9.01 0.6 Financed insurance premiums During the year ended December 31, 2022, the Company financed its directors’ and officers’ liability insurance in the amount of $ 399,949 9,402 1,497

STOCKHOLDERS_ EQUITY

STOCKHOLDERS’ EQUITY	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
STOCKHOLDERS’ EQUITY	NOTE 8 - STOCKHOLDERS’ EQUITY In June 2021, the Company amended and restated its Certificate of Incorporation to authorize 150,000,000 1,500,000 0.0001 250,000,000 no Preferred Stock On January 31, 2023, the Board of Directors declared a dividend of 0.001 0.0001 Warrants On March 31, 2023, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 70,969 $ 2,400.00 2,760.00 LACQ warrants Equity (b) 4,608 $ 8.58 Share subscription facility Equity (c) 4,512 $ 187.20 2021 Notes Liability (d) 38,894 $ 24.07 2022 Notes Liability (e) 549,987 $ 16.80 Public offering Equity (f) 318,451 $ 8.84 Public offering Equity 987,421 a) On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 3,477.60 11.6 The warrants have been subject to multiple exercise price reductions as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price (primarily the result of the conversions of the 2021 Notes and the 2022 Notes). The adjustments have progressed from the original exercise price of $ 2,402.40 8.58 c) On September 24, 2021 and November 5, 2021, the Company issued 1,504 3,008 1,831.20 September 23, 2026 187.20 d) On July 1, 2022 and August 9, 2022, the Company issued 19,447 170.04 June 29, 2027 August 8, 2027 24.07 e) On December 9, 2022, the Company issued 549,987 16.80 December 9, 2027 f) On February 6, 2023, the Company issued 318,451 8.58 12.60 February 2, 2028 August 7, 2028 The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) $ 3,477.60 $ 2,400.00 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) $ 3,477.60 $ 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) $ 7.01 1,029.60 $ 8.58 1,080.00 1.41 2.49 92.6% 125.3 % 1.0% 4.9 % (c) Liability classified warrants (grant date 9/24/21) $ 1,077.60 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) $ 540.00 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 3/31/23) $ 4.86 $ 187.20 3.50 3.60 102.9% 103.4 % 3.8 % (d) Liability classified warrants (grant date 7/1/22) $ 136.80 $ 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) $ 127.20 $ 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 3/31/23) $ 4.86 $ 24.07 4.25 4.36 101.2% 102.1 % 3.6 %

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	NOTE 9 - STOCK-BASED COMPENSATION In connection with the Business Combination, the Company assumed the 2021 Omnibus Incentive Plan (the “2021 Omnibus Plan”), which was approved by LACQ’s board and subsequently LACQ’s stockholders at a special stockholder meeting on June 28, 2021. The 2021 Omnibus Plan provides for the conversion with existing terms of the 18,432 4,166 In January 2022, the 2021 Omnibus Plan was amended and restated to include an additional 12,500 26,725 The Company recognized within general and administrative expense stock-based compensation expense of $ 96,270 373,944 20,863 28,490 Option Activity There were no stock options granted during the three months ended March 31, 2023. During the three months ended March 31, 2022, the Company granted stock options to purchase an aggregate of 8,275 zero four years 259.20 1,507.20 The following table summarizes the Company’s stock option activity during the three months ended March 31, 2023: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2022 26,334 $ 707.63 6.53 $ - Granted - - - - Exercised - - - - Expired / Forfeited - - - - Outstanding at March 31, 2023 26,334 $ 707.63 6.29 - Exercisable at March 31, 2023 23,922 729.16 - - Vested and expected to vest 26,334 $ 707.63 6.29 - Option Valuation The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2023): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Three Months Ended March 31, 2022 Exercise price $ 259.20 1,507.20 Expected stock price volatility 76.12% 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52% 2.20 % Expected dividend yield 0 % ● Expected stock-price volatility. ● Expected term. ● Risk-free interest rate. ● Expected dividend yield. The weighted-average grant date fair value of options granted during the three months ended March 30, 2022 was $ 1.01 As of March 31, 2023, the Company had an aggregate of $ 296,845 1.48 Restricted Stock Units The following table summarizes the Company’s restricted stock units activity during the three months ended March 31, 2023: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weighted average fair value Outstanding at December 31, 2022 1,003 $ 120.02 Released (312 ) 101.40 Outstanding at March 31, 2023 691 $ 128.43 There were no restricted stock units granted or forfeited during the three months ended March 31, 2023. The remaining awards outstanding are subject to time-based vesting conditions and are scheduled to vest by December 2023. The estimated fair value of each of the Company’s was determined on the date of grant based on the closing price of the Company’s common stock on the previous trading date. Shares Reserved for Future Issuance The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE March 31, 2023 Awards outstanding under the 2021 Omnibus Incentive Plan 27,025 Awards available for future grant under 2021 Omnibus Incentive Plan 31,294 Warrants outstanding 987,421 Total shares of common stock reserved for future issuance 1,045,740

RELATED PARTIES

RELATED PARTIES	3 Months Ended
	Mar. 31, 2023
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 10 - RELATED PARTIES On December 9, 2022, the Company completed a public offering for the sale of 241,666 16.80 550,000 16.80 29,761 59,523 In July 2022, the Chief Executive Officer and a Board member transferred 3,838 0.8 3,838

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended
	Mar. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 11 – SUBSEQUENT EVENTS On May 12, 2023, the Company completed a public offering of an aggregate of 1,800,876 1,800,876 1,800,876 3.637 3.637 7.0 On May 12, 2023, the Company paid $ 0.6

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
Use of estimates and assumptions	Use of estimates and assumptions Preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and disclosed in the accompanying notes. Actual results may differ from those estimates and such differences may be material to the consolidated financial statements. The more significant estimates and assumptions by management include, but are not limited to, the expense recognition for certain accrued research and development services, the valuation allowance of deferred tax assets resulting from net operating losses, and the fair value of warrants and options to purchase the Company’s common stock and convertible notes payable.
Cash and cash equivalents	Cash and cash equivalents For purposes of the consolidated balance sheets and consolidated statements of cash flows, the Company considers all highly liquid instruments with maturity of three months or less at the time of issuance to be cash equivalents.
Concentrations of credit risk and off-balance sheet risk	Concentrations of credit risk and off-balance sheet risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. The Company’s cash and cash equivalents are deposited in accounts at large financial institutions and amounts currently exceed federally insured limits. The Company has no financial instruments with off-balance sheet risk of loss.
Property and equipment	Property and equipment Property and equipment include office and laboratory equipment that is recorded at cost and depreciated using the straight-line method over the estimated useful lives of five six years
Derivative financial instruments	Derivative financial instruments The Company does not use derivative instruments to hedge exposures to interest rate, market, or foreign currency risks. The Company evaluates all of its financial instruments, including notes payable, to determine whether such instruments are derivatives or contain features that qualify as embedded derivatives. Embedded derivatives must be separately measured from the host contract if all the requirements for bifurcation are met. The assessment of the conditions surrounding the bifurcation of embedded derivatives depends on the nature of the host contract and the features of the derivatives. Bifurcated embedded derivatives are recognized at fair value, with changes in fair value recognized in the consolidated statement of operations each period. Bifurcated embedded derivatives are classified with the related host contract in the Company’s consolidated balance sheet.
Fair Value Measurement	Fair Value Measurement ASC 820, Fair Value Measurements The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: Level 1: Quoted prices in active markets for identical assets or liabilities. Level 2: Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace. Level 3: Unobservable inputs which are supported by little, or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation. The Company evaluates assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level at which to classify them for each reporting period. This determination requires significant judgments to be made by the Company. As of March 31, 2023 and December 31, 2022, the recorded values of cash and cash equivalents, prepaid expenses, accounts payable, and accrued expenses and other liabilities approximate their fair values due to the short-term nature of these items. 2021 Notes In 2021 the Company issued convertible notes and elected the fair value option to account for the convertible notes as it believes the fair value option provides users of the financial statements with greater ability to estimate the outcome of future events as facts and circumstances change, particularly with respect to changes in the fair value of the common stock underlying the conversion option and redemption feature. The fair value estimate of the 2021 Notes was based on a discounted cash flow model and a Monte Carlo simulation, which represent Level 3 measurements. Significant assumptions include the discount rate used in the discounted cash flow model and the expected premium for conversion used in the Monte Carlo simulation. Changes in the fair value of the notes are recognized in other income (expense) for each reporting period. Refer to Note 7 for details of the terms and conditions of the 2021 Notes. 2022 Notes In July 2022 the Company issued convertible notes and the 2022 Notes are accounted for under ASC 480 – Distinguishing Liabilities from Equity, Warrants In 2021 the Company issued liability classified warrants in connection with the issuance of the 2021 Notes. In 2022 the Company issued liability classified warrants in connection with the issuance of the 2022 Notes. The warrants were liability classified due to certain cash settlement features and included in “Other long-term liabilities” on the consolidated balance sheets. The Company uses a Black Scholes model to estimate the fair value of the warrants. Changes in the fair value of the warrants are recognized in other income (expense) for each reporting period. Refer to Note 8 for details of the warrants. The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of March 31, 2023 and December 31, 2022. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 March 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants $ 91,318 $ - $ - $ 91,318 Total $ 91,318 $ - $ - $ 91,318 Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 - - 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925 The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the quarter ended March 31, 2023: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible note Liability classified warrants Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346 Conversions (3,056,892 ) (3,056,892 ) - Cash payments (415,351 ) (415,351 ) - Cash true-up liability (584,857 ) (584,857 ) - Change in fair value (365,507 ) (146,479 ) (219,028 ) Fair value, March 31, 2023 $ 91,318 $ - $ 91,318
Federal Grants	Federal Grants In September 2018, the National Institutes of Health (“NIH”) through the National Institute on Drug Abuse (“NIDA”) awarded the Company a research and development grant related to the development of its MPAR TM 5.4 3.2 2.2 1.1 5.1 2.1 3.0 2.8 2.8 10.7 In September 2019, the NIH/NIDA awarded the Company a second research and development grant related to the development of its TAAP/MPAR TM 5.4 The Company recognizes revenue when costs related to the grants are incurred and assessed as reimbursable. The Company believes this policy is consistent with the overarching premise in Accounting Standards Codification Topic 606, Revenue from Contracts with Customers The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2023 2022 Three Months Ended March 31, 2023 2022 MPAR $ 481,279 $ 504,470 TAAP/OUD 308,356 98,628 Total $ 789,635 $ 603,098 Revenue $ 789,635 $ 603,098 Amounts requested or eligible to be requested through the NIH payment management system, but for which cash has not been received, are presented as an unbilled receivable on the Company’s consolidated balance sheet. As all amounts are expected to be remitted timely, no valuation allowances are recorded.
Research and development costs	Research and development costs The Company’s research and development expenses consist primarily of third-party research and development expenses, consulting expenses, animal and clinical studies, and any allocable direct overhead, including facilities and depreciation costs, as well as salaries, payroll taxes, and employee benefits for those individuals directly involved in ongoing research and development efforts. Research and development expenses are charged to expense as incurred. Payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received.
General and administrative expenses	General and administrative expenses General and administrative expenses consist primarily of personnel costs associated with the Company’s executive, finance, human resources, compliance, and other administrative personnel, as well as accounting and legal professional services fees.
Stock-based compensation	Stock-based compensation The Company expenses stock-based compensation over the requisite service period based on the estimated grant-date fair value of the awards using a graded amortization approach. The Company accounts for forfeitures as they occur. The Company estimates the fair value of stock option grants using the Black-Scholes option pricing model. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. For the three months ended March 31, 2023, stock-based compensation costs are recorded in general and administrative expenses and research and development expenses in the consolidated statements of operations. From time-to-time equity classified awards may be modified. On the modification date, the Company estimates the fair value of the awards immediately before and immediately after modification. The incremental increase in fair value is recognized as expense immediately to the extent the underlying equity awards are vested and over the same remaining amortization schedule as the unvested underlying equity awards.
Income taxes	Income taxes Income taxes are recorded in accordance with ASC 740, Income Taxes The Company accounts for uncertain tax positions in accordance with the provisions of ASC 740. When uncertain tax positions exist, the Company recognizes the tax benefit of tax positions to the extent that the benefit would more likely than not be realized assuming examination by the taxing authority. The determination as to whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as consideration of the available facts and circumstances. The Company recognizes any interest and penalties accrued related to unrecognized tax benefits as income tax expense.
Earnings per share	Earnings per share The basic earnings per share is calculated by dividing the Company’s net income or loss attributable to common stockholders by the weighted average number of common shares outstanding during the period. The diluted earnings per share is calculated by dividing the Company’s net earnings attributable to common stockholders by the diluted weighted average number of common shares outstanding during the period, determined using the treasury stock method and the average stock price during the period. The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2023 2022 Three Months Ended March 31, 2023 2022 Stock options 26,354 24,111 RSUs 691 1,788 Warrants 858,609 87,878 Convertible notes - 5,437 Total 885,654 119,214 Anti-dilutive weighted average shares 885,654 119,214
Recently Issued Accounting Pronouncements	Recently Issued Accounting Pronouncements In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and Other Options (Topic 470) to address issues identified as a result of the complexity with applying GAAP for certain financial instruments with characteristics of liabilities and equity. The FASB decided to reduce the number of accounting models for convertible debt instruments and convertible preferred stock, resulting in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Certain types of convertible instruments will continue to be subject to separation models: (a) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (b) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. For convertible instruments, the contracts primarily affected are those with beneficial conversions or cash conversion features as the accounting models for those specific features have been removed. For contracts in an entity’s own equity, the contracts primarily affected are freestanding instruments and embedded features that are accounted for as derivatives due to a failure to meet the settlement conditions of the derivatives scope exceptions. The FASB simplified the settlement assessment by removing the requirements to (a) consider whether the contract would be settled in registered shares, (b) to consider whether collateral is required to be posted, and (c) assess shareholder rights. The FASB also decided to enhance information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share guidance. ASU 2020-06 is effective for fiscal years beginning after December 15, 2023 and early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020. Entities must adopt the guidance as of the beginning of its annual fiscal year and a modified retrospective or fully retrospective transition approach is permitted. The Company adopted the standard with an effective date of January 1, 2023 and the adoption did not have a significant impact on the consolidated financial statements.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	3 Months Ended
	Mar. 31, 2023
Accounting Policies [Abstract]
SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE	The following tables present liabilities measured and recorded at fair value on the Company’s consolidated balance sheets as of March 31, 2023 and December 31, 2022. SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE Total Level 1 Level 2 Level 3 March 31, 2023 Total Level 1 Level 2 Level 3 Liability classified warrants $ 91,318 $ - $ - $ 91,318 Total $ 91,318 $ - $ - $ 91,318 Total Level 1 Level 2 Level 3 December 31, 2022 Total Level 1 Level 2 Level 3 Fair value of convertible note $ 4,203,579 $ - $ - $ 4,203,579 Liability classified warrants 310,346 - - 310,346 Total $ 4,513,925 $ - $ - $ 4,513,925
SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3	The following table summarizes the change in fair value of the Company’s Level 3 assets and liabilities for the quarter ended March 31, 2023: SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 Total Convertible note Liability classified warrants Fair value, December 31, 2022 $ 4,513,925 $ 4,203,579 $ 310,346 Conversions (3,056,892 ) (3,056,892 ) - Cash payments (415,351 ) (415,351 ) - Cash true-up liability (584,857 ) (584,857 ) - Change in fair value (365,507 ) (146,479 ) (219,028 ) Fair value, March 31, 2023 $ 91,318 $ - $ 91,318
SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS	The revenue recognized under the MPAR Grant and OUD Grant was as follows: SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS 2023 2022 Three Months Ended March 31, 2023 2022 MPAR $ 481,279 $ 504,470 TAAP/OUD 308,356 98,628 Total $ 789,635 $ 603,098 Revenue $ 789,635 $ 603,098
SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES	The following weighted average shares have been excluded from the calculations of diluted weighted average common shares outstanding because they would have been anti-dilutive: SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES 2023 2022 Three Months Ended March 31, 2023 2022 Stock options 26,354 24,111 RSUs 691 1,788 Warrants 858,609 87,878 Convertible notes - 5,437 Total 885,654 119,214 Anti-dilutive weighted average shares 885,654 119,214

PREPAID EXPENSES AND OTHER CU_2

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)	3 Months Ended
	Mar. 31, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS	SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS March 31, 2023 December 31, 2022 Prepaid research and development $ 1,180,547 $ 1,300,473 Prepaid insurance 314,990 445,583 Other prepaid expenses 151,016 101,425 Total prepaid expenses and other current assets $ 1,646,553 $ 1,847,481

ACCRUED EXPENSES AND OTHER LI_2

ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)	3 Months Ended
	Mar. 31, 2023
Payables and Accruals [Abstract]
SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES	SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES March 31, 2023 December 31, 2022 Accrued research and development $ 1,293,348 $ 1,332,713 Share subscription facility commitment fees - 400,000 Professional fees 393,077 421,530 Other accrued liabilities 672,257 72,251 Total accrued expenses and other liabilities $ 2,358,682 $ 2,226,494

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	3 Months Ended
	Mar. 31, 2023
Short-Term Debt [Line Items]
SCHEDULE OF DEBT	The following table provides a summary of the Company’s outstanding debt as of December 31, 2022: SCHEDULE OF DEBT Principal balance Accrued interest Fair value adjustment Net debt balance 2022 Notes $ 3,905,264 $ 10,544 $ 287,771 $ 4,203,579 Financed insurance 195,273 7,906 - 203,179 Total $ 4,100,537 $ 18,450 $ 287,771 $ 4,406,758
SCHEDULE OF INTEREST EXPENSE DEBT	The interest expense recognized for financed insurance was as follows: SCHEDULE OF INTEREST EXPENSE DEBT 2023 2022 Three months ended March 31, 2023 2022 Stated interest accrual $ 1,497 $ 2,004 Total $ 1,497 $ 2,004
2022 Notes [Member]
Short-Term Debt [Line Items]
SCHEDULE OF CONVERSION DEBT	The following table provides a summary of the Company’s 2022 Notes conversions during the quarter ended March 31, 2023: SCHEDULE OF CONVERSION DEBT Shares Weighted Average Conversion Price Conversion Value During the quarter ended March 31, 2023 408,582 $ 7.48 $ 3,056,892

STOCKHOLDERS_ EQUITY (Tables)

STOCKHOLDERS’ EQUITY (Tables)	3 Months Ended
	Mar. 31, 2023
Equity [Abstract]
SCHEDULE OF OUTSTANDING WARRANT	On March 31, 2023, outstanding warrants to purchase shares of common stock are as follows: SCHEDULE OF OUTSTANDING WARRANT Reference Shares Underlying Outstanding Warrants Exercise Price Description Classification (a) 70,969 $ 2,400.00 2,760.00 LACQ warrants Equity (b) 4,608 $ 8.58 Share subscription facility Equity (c) 4,512 $ 187.20 2021 Notes Liability (d) 38,894 $ 24.07 2022 Notes Liability (e) 549,987 $ 16.80 Public offering Equity (f) 318,451 $ 8.84 Public offering Equity 987,421 a) On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 On August 3, 2021, the Company entered into an agreement with an existing warrant holder to reduce the price of 2,083 2,760.00 2,400.00 b) On July 2, 2021, upon public listing of the Company’s shares, the Company issued 4,608 three 3,477.60 11.6 The warrants have been subject to multiple exercise price reductions as required by a down round adjustment feature of the warrant, due to common stock issued at a price below the then current exercise price (primarily the result of the conversions of the 2021 Notes and the 2022 Notes). The adjustments have progressed from the original exercise price of $ 2,402.40 8.58 c) On September 24, 2021 and November 5, 2021, the Company issued 1,504 3,008 1,831.20 September 23, 2026 187.20 d) On July 1, 2022 and August 9, 2022, the Company issued 19,447 170.04 June 29, 2027 August 8, 2027 24.07 e) On December 9, 2022, the Company issued 549,987 16.80 December 9, 2027 f) On February 6, 2023, the Company issued 318,451 8.58 12.60 February 2, 2028 August 7, 2028
SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS	The fair value of each warrant issued has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the warrants issued for the periods presented were as follows: SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS Stock price Exercise price Expected term (years) Volatility Risk free rate (a) LACQ warrants (grant date varies) $ 3,477.60 $ 2,400.00 2,760.00 3.00 110.0 % 0.5 % (b) Share subscription facility (grant date 7/2/21) $ 3,477.60 $ 2,402.40 3.00 110.0 % 0.5 % (b) Share subscription facility (remeasurement date varies) $ 7.01 1,029.60 $ 8.58 1,080.00 1.41 2.49 92.6% 125.3 % 1.0% 4.9 % (c) Liability classified warrants (grant date 9/24/21) $ 1,077.60 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (grant date 11/5/21) $ 540.00 $ 1,831.20 5.00 94.1 % 1.0 % (c) Liability classified warrants (remeasured at 3/31/23) $ 4.86 $ 187.20 3.50 3.60 102.9% 103.4 % 3.8 % (d) Liability classified warrants (grant date 7/1/22) $ 136.80 $ 170.04 5.00 98.9 % 2.9 % (d) Liability classified warrants (grant date 8/9/22) $ 127.20 $ 170.04 5.00 102.8 % 3.0 % (d) Liability classified warrants (remeasured at 3/31/23) $ 4.86 $ 24.07 4.25 4.36 101.2% 102.1 % 3.6 %

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
SCHEDULE OF STOCK OPTION ACTIVITY	The following table summarizes the Company’s stock option activity during the three months ended March 31, 2023: SCHEDULE OF STOCK OPTION ACTIVITY Weighted average Options Exercise price Remaining contractual life Intrinsic value Outstanding at December 31, 2022 26,334 $ 707.63 6.53 $ - Granted - - - - Exercised - - - - Expired / Forfeited - - - - Outstanding at March 31, 2023 26,334 $ 707.63 6.29 - Exercisable at March 31, 2023 23,922 729.16 - - Vested and expected to vest 26,334 $ 707.63 6.29 -
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS	The fair value of each stock option granted has been determined using the Black-Scholes option-pricing model. The material assumptions used in the Black-Scholes model in estimating the fair value of the options granted for the periods presented were as follows (there were no grants issued in 2023): SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Three Months Ended March 31, 2022 Exercise price $ 259.20 1,507.20 Expected stock price volatility 76.12% 95.87 % Expected term (years) 5.19 10.00 Risk-free interest rate 1.52% 2.20 % Expected dividend yield 0 %
SCHEDULE OF RESTRICTED STOCK UNITS	The following table summarizes the Company’s restricted stock units activity during the three months ended March 31, 2023: SCHEDULE OF RESTRICTED STOCK UNITS Restricted Stock Units Weighted average fair value Outstanding at December 31, 2022 1,003 $ 120.02 Released (312 ) 101.40 Outstanding at March 31, 2023 691 $ 128.43
SCHEDULE OF COMMON STOCK FUTURE ISSUANCE	The following shares of common stock are reserved for future issuance: SCHEDULE OF COMMON STOCK FUTURE ISSUANCE March 31, 2023 Awards outstanding under the 2021 Omnibus Incentive Plan 27,025 Awards available for future grant under 2021 Omnibus Incentive Plan 31,294 Warrants outstanding 987,421 Total shares of common stock reserved for future issuance 1,045,740

ORGANIZATION AND PRINCIPAL AC_2

ORGANIZATION AND PRINCIPAL ACTIVITIES (Details Narrative) - $ / shares	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2021	Dec. 31, 2020
Common stock, shares authorized	250,000,000	250,000,000	250,000,000	150,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	1,500,000	1,500,000		1,500,000
Preferred stock, par value	$ 0.0001	$ 0.0001		$ 0.0001
EBIR, Inc [Member]
Common stock, shares authorized					1,000,000
Common stock, par value					$ 0.001
Preferred stock, shares authorized					100,000
Preferred stock, par value					$ 0.001
EBIR, Inc [Member]
Ownership percentage	79.20%
EBIR, Inc [Member] | Key Personnel [Member]
Ownership percentage	19.80%
EBIR, Inc [Member] | Unrelated Party [Member]
Ownership percentage	1%

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	1 Months Ended
	Mar. 31, 2023	Jul. 31, 2022	Jun. 30, 2021	Dec. 31, 2022	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021	Jul. 02, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Reverse stock split	1-for-12 reverse split
Accumulated deficit	$ 113,127,237			$ 110,931,063
Common stock, subscriptions value										$ 60,000,000
Warrants issued shares			78,751		19,447	19,447	3,008	1,504	4,608
Warrant, exercise price	$ 8.58				$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20
July 2022 [Member] | Common Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Commitment fees		$ 800,000
January 2023 [Member] | Common Stock [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Commitment fees		$ 400,000
Investor [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Warrants issued shares			4,608
Warrant, exercise price			$ 2,402.40
Commitment fees			$ 1,200,000
Investor [Member] | First Anniversary [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Commitment fees			800,000
Investor [Member] | 18-Month Anniversary [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-Based Payments and Postretirement Benefits [Line Items]
Commitment fees			$ 400,000

SCHEDULE OF ASSETS AND LIABILIT

SCHEDULE OF ASSETS AND LIABILITIES MEASURED AT FAIR VALUE (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Platform Operator, Crypto-Asset [Line Items]
Liability classified warrants	$ 91,318	$ 310,346
Total	91,318	4,513,925
Fair value of convertible note		4,203,579
Fair Value, Inputs, Level 1 [Member]
Platform Operator, Crypto-Asset [Line Items]
Liability classified warrants
Total
Fair value of convertible note
Fair Value, Inputs, Level 2 [Member]
Platform Operator, Crypto-Asset [Line Items]
Liability classified warrants
Total
Fair value of convertible note
Fair Value, Inputs, Level 3 [Member]
Platform Operator, Crypto-Asset [Line Items]
Liability classified warrants	91,318	310,346
Total	$ 91,318	4,513,925
Fair value of convertible note		$ 4,203,579

SCHEDULE OF CHANGE IN FAIR VALU

SCHEDULE OF CHANGE IN FAIR VALUE OF COMPANY’S LEVEL 3 (Details)	3 Months Ended
	Mar. 31, 2023 USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 4,513,925
Conversions	(3,056,892)
Cash payments	(415,351)
Cash true-up liability	(584,857)
Change in fair value	(365,507)
Ending balance	91,318
Convertible Notes [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	4,203,579
Conversions	(3,056,892)
Cash payments	(415,351)
Cash true-up liability	(584,857)
Change in fair value	(146,479)
Ending balance
Liability Classified Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	310,346
Conversions
Cash payments
Cash true-up liability
Change in fair value	(219,028)
Ending balance	$ 91,318

SCHEDULE OF REVENUE RECOGNIZATI

SCHEDULE OF REVENUE RECOGNIZATION UNDER GRANTS (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Product Information [Line Items]
Revenue	$ 789,635	$ 603,098
MPAR [Member]
Product Information [Line Items]
Revenue	481,279	504,470
TAAP/OUD [Member]
Product Information [Line Items]
Revenue	$ 308,356	$ 98,628

SCHEDULE OF WEIGHTED AVERAGE SH

SCHEDULE OF WEIGHTED AVERAGE SHARES OF ANTI-DILUTIVE SECURITIES (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	885,654	119,214
Share-Based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	26,354	24,111
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	691	1,788
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares	858,609	87,878
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive weighted average shares		5,437

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Millions	Mar. 31, 2023	Jun. 30, 2022	Jun. 30, 2021	Sep. 30, 2019	Aug. 31, 2019	Sep. 30, 2018
Property, Plant and Equipment [Line Items]
Grants receivable		$ 10.7		$ 5.4	$ 5.1	$ 5.4
Year 1 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable					2.1	3.2
Contribution of grants						1.1
Year 2 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable					$ 3	$ 2.2
Year 3 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable			$ 2.8
Year 4 [Member]
Property, Plant and Equipment [Line Items]
Grants receivable		$ 2.8
Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	5 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and equipment estimated useful lives	6 years

SCHEDULE OF PREPAID EXPENSES AN

SCHEDULE OF PREPAID EXPENSES AND OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Prepaid research and development	$ 1,180,547	$ 1,300,473
Prepaid insurance	314,990	445,583
Other prepaid expenses	151,016	101,425
Total prepaid expenses and other current assets	$ 1,646,553	$ 1,847,481

SCHEDULE OF ACCRUED EXPENSES AN

SCHEDULE OF ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued research and development	$ 1,293,348	$ 1,332,713
Share subscription facility commitment fees		400,000
Professional fees	393,077	421,530
Other accrued liabilities	672,257	72,251
Total accrued expenses and other liabilities	$ 2,358,682	$ 2,226,494

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Contractual obligation	$ 20,400,000
Future lease payments	19,120
Rent expense	$ 8,375	$ 7,834

SCHEDULE OF DEBT (Details)

SCHEDULE OF DEBT (Details) - USD ($)	Mar. 31, 2023	Jan. 12, 2023	Dec. 31, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Principal balance			$ 4,100,537
Accrued interest			18,450
Fair value adjustment			287,771
Net debt balance	$ 0	$ 600,000	4,406,758
2022 Notes [Member]
Short-Term Debt [Line Items]
Principal balance			3,905,264
Accrued interest			10,544
Fair value adjustment			287,771
Net debt balance			4,203,579	$ 4,240,000
Financed Insurance [Member]
Short-Term Debt [Line Items]
Principal balance			195,273
Accrued interest			7,906
Fair value adjustment
Net debt balance			$ 203,179

SCHEDULE OF INTEREST EXPENSE DE

SCHEDULE OF INTEREST EXPENSE DEBT (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Debt Disclosure [Abstract]
Stated interest accrual	$ 1,497	$ 2,004
Total	$ 1,497	$ 2,004

SCHEDULE OF CONVERSION DEBT (De

SCHEDULE OF CONVERSION DEBT (Details) - 2022 Notes [Member] - Note One [Member]	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Short-Term Debt [Line Items]
Debt conversion date	Mar. 31, 2023
Shares | shares	408,582
Weighted Average Conversion Price | $ / shares	$ 7.48
Conversion Value | $	$ 3,056,892

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)				3 Months Ended		12 Months Ended	15 Months Ended
	Jun. 30, 2022	Nov. 05, 2021	Sep. 24, 2021	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Mar. 31, 2023	May 12, 2023	Jan. 12, 2023	Aug. 09, 2022	Jul. 31, 2022	Jul. 01, 2022	Aug. 03, 2021	Jun. 30, 2021
Short-Term Debt [Line Items]
Net debt balance				$ 0		$ 4,406,758	$ 0		$ 600,000
Exercise price		$ 1,831.20	$ 1,831.20	$ 8.58			$ 8.58			$ 170.04		$ 170.04
Original issue discount rate percentage				8%			8%
Financed insurance premiums						399,949
Interest expense				$ 1,497	$ 15,021
Financed Insurance Premiums [Member]
Short-Term Debt [Line Items]
Interest expense				$ 1,497			$ 9,402
Maximum [Member]
Short-Term Debt [Line Items]
Exercise price													$ 2,760	$ 2,760
Minimum [Member]
Short-Term Debt [Line Items]
Exercise price				$ 2,402.40			$ 2,402.40						$ 2,400	$ 2,400
2021 Notes [Member]
Short-Term Debt [Line Items]
Convertible debt		$ 10,600,000	$ 5,300,000
Proceeds from convertible debt		$ 9,400,000	$ 4,600,000
Debt instrument, interest rate				5%
Debt instrument original issue discount				6%
Payments of debt issuance costs				$ 15,900,000
Debt issuance costs, net				1,900,000			$ 1,900,000
Legal fees				1,000,000
Amortization of financing costs				$ 900,000
Percentage of cash settlement premium				8%
Exercise price	$ 187.20
2022 Notes [Member]
Short-Term Debt [Line Items]
Net debt balance	$ 4,240,000					$ 4,203,579
Convertible debt	8,000,000
Cash proceeds from issuance of debt	4,000,000
Initial fair value	12,090,000
Loss on issuance of fair value	3,600,000
Issuance costs	$ 1,100,000
Original issue discount rate	6%
Original issue discount	$ 500,000
Legal and investment banking fees	$ 600,000
Warrants to purchase common stock	38,894
Exercise price	$ 170.04										$ 187.20
Debt term	5 years
Convertible debt				$ 5,000,000			$ 5,000,000
Original issue discount rate percentage				6%			6%
Debt interest rate				6%			6%
2022 Notes [Member] | Maximum [Member]
Short-Term Debt [Line Items]
Debt instrument, redemption price, percentage				20%
Debt maturity date				Feb. 07, 2024
2022 Notes [Member] | Minimum [Member]
Short-Term Debt [Line Items]
Debt maturity date				Dec. 29, 2023
2022 Notes [Member] | Common Stock [Member]
Short-Term Debt [Line Items]
Conversion price	$ 0.92
Two Thousand Twenty Three Notes [Member] | Letter Agreement [Member]
Short-Term Debt [Line Items]
Conversion price								$ 9.01	$ 24.07

SCHEDULE OF OUTSTANDING WARRANT

SCHEDULE OF OUTSTANDING WARRANT (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	987,421
Warrant One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	70,969	[1]
Warrant description	LACQ warrants	[1]
Warrant One [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 2,400	[1]
Warrant One [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Exercise price | $ / shares	$ 2,760	[1]
Warrant Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	4,608	[2]
Exercise price | $ / shares	$ 8.58	[2]
Warrant description	Share subscription facility	[2]
Warrant Three [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	4,512	[3]
Exercise price | $ / shares	$ 187.20	[3]
Warrant description	2021 Notes	[3]
Warrant Four [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	38,894	[4]
Exercise price | $ / shares	$ 24.07	[4]
Warrant description	2022 Notes	[4]
Warrant Five [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	549,987	[5]
Exercise price | $ / shares	$ 16.80	[5]
Warrant description	Public offering	[5]
Warrant Six [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Outstanding warrant | shares	318,451	[6]
Exercise price | $ / shares	$ 8.84	[6]
Warrant description	Public offering	[6]
[1]On June 30, 2021, as a result of the Closing, the Company assumed a total of 78,751 7,782 2,400.00 2,760.00 June 30, 2026 41,666 29,303 4,608 three 3,477.60 11.6 1,504 3,008 1,831.20 September 23, 2026 187.20 19,447 170.04 June 29, 2027 August 8, 2027 24.07 549,987 16.80 December 9, 2027 318,451 8.58 12.60 February 2, 2028 August 7, 2028

SCHEDULE OF OUTSTANDING WARRA_2

SCHEDULE OF OUTSTANDING WARRANT (Details) (Parenthetical) - USD ($) $ / shares in Units, $ in Millions

Jul. 02, 2021

Jun. 30, 2021

Mar. 31, 2023

Feb. 06, 2023

Dec. 31, 2022

Dec. 09, 2022

Aug. 09, 2022

Jul. 31, 2022

Jul. 01, 2022

Jun. 30, 2022

Nov. 05, 2021

Sep. 24, 2021

Aug. 03, 2021

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

4,608

78,751

19,447

19,447

3,008

1,504

Warrants cancelled

7,782

Warrants, exercise price

$ 8.58

$ 170.04

$ 170.04

$ 1,831.20

$ 1,831.20

Warrant expiration date

Jun. 30, 2026

Aug. 08, 2027

Jun. 29, 2027

Sep. 23, 2026

Sep. 23, 2026

Class of warrant or right, outstanding

550,000

Warrant term

3 years

2022 Notes [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 187.20

$ 170.04

December Public Offering [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 24.07

General and Administrative Expense [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Grant date fair value of warrants price per share

$ 3,477.60

Fair value adjustment of warrants

$ 11.6

Subscription Arrangement [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

2,083

Public Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of warrant or right, outstanding

41,666

Private Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Remaining of cashless warrant shares

29,303

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants issued

318,451

549,987

Warrants, exercise price

$ 16.80

Warrant expiration date

Dec. 09, 2027

Class of warrant or right, outstanding

59,523

Minimum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,400

$ 2,402.40

$ 2,400

Warrant expiration date

Feb. 02, 2028

Minimum [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 8.58

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 2,760

$ 2,760

Warrant expiration date

Aug. 07, 2028

Maximum [Member] | Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants, exercise price

$ 12.60

SCHEDULE OF WARRANTS FAIR VALUE

SCHEDULE OF WARRANTS FAIR VALUE ESTIMATION ASSUMPTIONS (Details)	Mar. 31, 2023 $ / shares	Aug. 09, 2022 $ / shares	Jul. 01, 2022 $ / shares	Nov. 05, 2021 $ / shares	Sep. 24, 2021 $ / shares	Jul. 02, 2021 $ / shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years						3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3,477.60
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,400
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	2,760
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years					3 years
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	110
Leisure Acquisition Corp A Delaware Corporation [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.5
Share Subscription Facility [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						3,477.60
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	7.01
Share Subscription Facility [Member] | Measurement Input, Share Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1,029.60
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						2,402.40
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	8.58
Share Subscription Facility [Member] | Measurement Input, Exercise Price [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1,080
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.010
Expected term years	1 year 4 months 28 days
Share Subscription Facility [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.9
Expected term years	2 years 5 months 26 days
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						110
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	0.926
Share Subscription Facility [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.253
Share Subscription Facility [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants						0.5
Liability Classified Warrants Grant Date [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		127.20	136.80	540	1,077.60
Liability Classified Warrants Grant Date [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		170.04	170.04	1,831.20	1,831.20
Liability Classified Warrants Grant Date [Member] | Measurement Input, Expected Term [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years		5 years	5 years	5 years	5 years
Liability Classified Warrants Grant Date [Member] | Measurement Input, Price Volatility [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		102.8	98.9	94.1	94.1
Liability Classified Warrants Grant Date [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants		3	2.9	1	1
Liability Classified Warrants Remeasured [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.86
Liability Classified Warrants Remeasured [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	187.20
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years 6 months
Liability Classified Warrants Remeasured [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	3 years 7 months 6 days
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.029
Liability Classified Warrants Remeasured [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	103.4
Liability Classified Warrants Remeasured [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3.8
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Share Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	4.86
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Exercise Price [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	24.07
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Expected Term [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 3 months
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Expected Term [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Expected term years	4 years 4 months 9 days
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Price Volatility [Member] | Minimum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	1.012
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Price Volatility [Member] | Maximum [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	102.1
Liability Classified Warrants Remeasured2 [Member] | Measurement Input, Risk Free Interest Rate [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Estimating fair value of warrants	3.6

STOCKHOLDERS_ EQUITY (Details N

STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares	Jan. 31, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2021
Class of Stock [Line Items]
Common stock, shares authorized		250,000,000	250,000,000	250,000,000	150,000,000
Preferred stock, shares authorized		1,500,000	1,500,000		1,500,000
Preferred stock, par value		$ 0.0001	$ 0.0001		$ 0.0001
Preferred stock, shares issued		0	0
Preferred stock, shares outstanding		0	0
Declared dividend per shares	$ 0.001
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, par value		$ 0.0001
Preferred stock voting rights	the Board of Directors declared a dividend of 0.001 of a share of Series A Preferred Stock, par value $0.0001 per share, for each outstanding share of the Company’s common stock to stockholders of record on February 13, 2023. Each full share of the Series A Preferred Stock entitled holders to 1,000,000 votes per share with respect to the reverse stock split proposal and the adjournment proposal at the Company’s special meeting of stockholders on March 23, 2023. The Series A Preferred Stock had no dividend rights and was fully redeemed following the effectiveness of a reverse stock split on March 31, 2023.

SCHEDULE OF STOCK OPTION ACTIVI

SCHEDULE OF STOCK OPTION ACTIVITY (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Option outstanding, beginning balance | shares	26,334
Weighted average exercise price. beginning balance	$ 707.63
Weighted average remaining contractual term, beginning balance	6 years 6 months 10 days
Aggregate intrinsic value, beginning balance | $
Option outstanding, granted | shares
Weighted average exercise price, granted
Aggregate intrinsic value, granted
Option outstanding, exercised | shares
Weighted average exercise price, exercised
Aggregate intrinsic value, exercised | $
Option outstanding, Expired or Forfeited | shares
Weighted average exercise price, expired / forfeited
Aggregate intrinsic value, expired or forfeited | $
Option outstanding, ending balance | shares	26,334
Weighted average exercise price, ending balance	$ 707.63
Weighted average remaining contractual term, ending balance	6 years 3 months 14 days
Aggregate intrinsic value, ending balance | $
Option, exercisable | shares	23,922
Weighted average exercise price, exercisable	$ 729.16
Aggregate intrinsic value, beginning balance | $
Option vested or expected to vest | shares	26,334
Weighted average exercise price, vested or expected to vest	$ 707.63
Weighted average remaining contractual term in years, vested and expected to vest	6 years 3 months 14 days
Aggregate intrinsic value, vested or expected to vest | $

SCHEDULE OF SHARE-BASED PAYMENT

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected stock price volatility, minimum	76.12%
Expected stock price volatility, maximum	95.87%
Risk-free interest rate, minimum	1.52%
Risk-free interest rate, maximum	2.20%
Expected dividend rate	0%
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 259.20
Expected term (years)	5 years 2 months 8 days
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Exercise price	$ 1,507.20
Expected term (years)	10 years

SCHEDULE OF RESTRICTED STOCK UN

SCHEDULE OF RESTRICTED STOCK UNITS (Details) - Restricted Stock Units (RSUs) [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Restricted stock units outstanding, beginning balance | shares	1,003
Weight average fair value, beginning balance | $ / shares	$ 120.02
Restricted stock units, released | shares	(312)
Weight average fair value, released | $ / shares	$ 101.40
Restricted stock units outstanding, ending balance | shares	691
Weight average fair value, ending balance | $ / shares	$ 128.43

SCHEDULE OF COMMON STOCK FUTURE

SCHEDULE OF COMMON STOCK FUTURE ISSUANCE (Details)	Mar. 31, 2023 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	1,045,740
Warrant Outstanding [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	987,421
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	27,025
Share-Based Payment Arrangement, Option [Member] | Stock Option Available For Future Grant Under 2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance	31,294

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Feb. 28, 2023	Dec. 31, 2022	Jan. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	26,334			26,334
Shares available for future grant	1,045,740
Number of restricted stock granted
Exercise price per share vested	$ 707.63
Weighted-average fair value per share , grant		$ 1.01
Unrecognized stock based compensation	$ 296,845
Weighted average period	1 year 5 months 23 days
Minimum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period		0 years
Exercise price per share vested		$ 259.20
Maximum [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, vesting period		4 years
Exercise price per share vested		$ 1,507.20
Board of Members [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of restricted stock granted		8,275
General and Administrative Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 96,270	$ 373,944
Research and Development Expense [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation expense	$ 20,863	$ 28,490
2021 Omnibus Incentive Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Option, outstanding	18,432
Shares available for future grant	4,166		26,725		12,500

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - USD ($)		1 Months Ended		3 Months Ended
	Dec. 09, 2022	Oct. 31, 2022	Jul. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Subsidiary, Sale of Stock [Line Items]
Settlement of restricted stock units, shares		3,838
Share price	$ 16.80
Warrants in public offering	550,000
Settlement of restricted stock units				$ 2,689,052
Chief Executive Officer And Board Member [Member]
Subsidiary, Sale of Stock [Line Items]
Settlement of restricted stock units, shares			3,838
Settlement of restricted stock units			$ 800,000
Warrant [Member]
Subsidiary, Sale of Stock [Line Items]
Settlement of restricted stock units, shares	29,761
Share price	$ 16.80
Warrants in public offering	59,523
IPO [Member]
Subsidiary, Sale of Stock [Line Items]
Settlement of restricted stock units, shares	241,666

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	May 12, 2023	Mar. 31, 2023	Jan. 12, 2023	Dec. 31, 2022	Aug. 09, 2022	Jul. 01, 2022	Nov. 05, 2021	Sep. 24, 2021
Subsequent Event [Line Items]
Warrant, exercise price		$ 8.58			$ 170.04	$ 170.04	$ 1,831.20	$ 1,831.20
Notes Payable		$ 0	$ 600,000	$ 4,406,758
Subsequent Event [Member]
Subsequent Event [Line Items]
Sale of stock number of shares issued in transaction	1,800,876
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right	1,800,876
Warrant, exercise price	$ 3.637
Sale of Stock, Consideration Received Per Transaction	$ 7,000,000
Notes Payable	$ 600,000